Combination of GNS561 and Trametinib in Patients with Advanced KRAS Mutated Cholangiocarcinoma
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Genfit
- Target Recruit Count
- 74
- Registration Number
- NCT05874414
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University Of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Genfit
- Target Recruit Count
- 77
- Registration Number
- NCT05368935
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Genfit
- Target Recruit Count
- 25
- Registration Number
- NCT05116826
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Genfit
- Target Recruit Count
- 21
- Registration Number
- NCT04171752
- Locations
- 🇫🇷
BIOTRIAL, Rennes, France
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Genfit
- Target Recruit Count
- 26
- Registration Number
- NCT03985969
- Locations
- 🇫🇷
Eurofins Optimed Clinical Pharmacology Unit, Gières, France
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Genfit
- Target Recruit Count
- 17
- Registration Number
- NCT03953456
- Locations
- 🇳🇱
NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, Netherlands
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Genfit
- Target Recruit Count
- 10
- Registration Number
- NCT03883607
- Locations
- 🇺🇸
University of California, San Diego, California, United States
🇺🇸Columbia University, New York, New York, United States
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
- Conditions
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Genfit
- Target Recruit Count
- 23
- Registration Number
- NCT03844555
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
🇷🇴ARENSIA Exploratory Medicine Unit, Nephrology Hospital Dr. Carol Davilla, Bucharest, Romania
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Genfit
- Target Recruit Count
- 30
- Registration Number
- NCT03765671
- Locations
- 🇺🇸
inVentiv Health Clinical Research, Miami, Florida, United States
🇺🇸Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
- Conditions
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Genfit
- Target Recruit Count
- 45
- Registration Number
- NCT03124108
- Locations
- 🇪🇸
Hospital De La Sant Creu St. Pau, Barcelona, Spain
🇬🇧King's College Hospital, London, United Kingdom
🇺🇸Cleveland Clinic Florida, Weston, Florida, United States